Sarepta Therapeutics, Inc. (SRPT) Earnings Call Transcripts
Sarepta Therapeutics, Inc.'s Latest Earnings Call - June 4, 2026
During the 2026 Annual Meeting of Stockholders for Sarepta Therapeutics, management highlighted the company's stability amidst recent turmoil, particularly with the planned retirement of CEO Doug Ingram later this year. The meeting confirmed the approval of key proposals, including the 2026 equity incentive plan and employee stock purchase plan, which are crucial for talent retention. While specific financial metrics were not disclosed, management indicated that first-quarter results were in line with expectations, suggesting a cautious but stable outlook for the fiscal year.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | |
| Earnings Per Share (EPS) | |
| Operating Margin | |
| Equity Incentive Plan Approval | Approved (positive) |
| Employee Stock Purchase Plan Approval | Approved (positive) |
Guidance from management
Management did not provide specific numerical guidance for the upcoming quarters but indicated that they are making significant progress towards their performance goals for 2026.
What management said
At this time, we will take questions from the [indiscernible]. When submitting questions, please indicate your name business affiliation and whether you are a stockholder aid or a proxy or a stock. Please note, we will attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed.
The first question is actually not directed to the company. It's directed to large shareholders, and there are no large shareholders currently taking part of the meeting. So the question is inappropriate nor to be answered here. The second question we've received is around Mr. Ingram and Mr. Wigzell's reelection to the Board, direct the shareholder rate proposal requesting that they no longer be on the Board, but [...
What analysts pressed on
Analysts expressed concerns regarding the timing of executive compensation in light of leadership changes, questioning the appropriateness of the recent pay package awarded to Ingram prior to his announced retirement. There were also inquiries about board stability and performance metrics relative to peers.
Main topics on the call
- CEO Transition — CEO Doug Ingram is set to retire later this year, with a search for his successor underway. Dr. Behrens emphasized the importance of continuity during this transition, stating, "it's extremely important that we retain bo...
- Equity Incentive Plan Approval — The 2026 equity incentive plan was approved, which management described as a necessary tool to align executive interests with those of shareholders. They stated, "the 2026 plan is a standard necessary tool to attract and...
- Employee Stock Purchase Plan — The employee stock purchase plan was also approved, reinforcing the company's commitment to employee engagement and retention. This aligns with management's focus on stability and performance improvement.
- Board Stability — Management underscored the need for stability in the board during a tumultuous period, with Dr. Behrens noting, "it's been a very tumultuous 12 months for the company." This sentiment reflects ongoing concerns about comp...
Read the full Sarepta Therapeutics, Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 92 calls on record spanning January 13, 2020 to August 5, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 92 Sarepta Therapeutics, Inc. earnings call transcripts on record, spanning January 13, 2020 to August 5, 2026. Based on this history, Sarepta Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SRPT
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 92
- First call
- January 13, 2020
- Most recent
- August 5, 2026
- Reporting cadence
- quarterly